The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Validation of HER2 Amplification as a Predictive Biomarker for Anti–Epidermal Growth Factor Receptor Antibody Therapy in Metastatic Colorectal Cancer
Abstract
Purpose: HER2 amplification has been implicated in resistance to therapy with anti–epidermal growth factor receptor antibodies (anti-EGFRabs) in metastatic colorectal cancer (mCRC). The purpose of the study was to validate the predictive impact of HER2 amplification in mCRC. Patients and Methods: We analyzed patients with RAS/BRAF wild-type mCRC across two distinct cohorts. In cohort 1 (n = 98), HER2 amplification was tested in tumor tissue using dual in situ hybridization ( HER2 amplification: HER2/CEP17 ratio, 2.0 or greater). Cohort 2 (n = 70) included 16 patients with HER2 amplification and 54 HER2 nonamplified controls identified by next-generation sequencing ( HER2 amplification: four or more copies) who had received prior anti-EGFRabs. The primary end point was progression-free survival (PFS) on treatment with anti-EGFRab therapy, which was estimated and compared using the Kaplan-Meier method and log-rank test. Results: Median PFS in cohort 1 on anti-EGFRab–based therapy was significantly shorter in patients with HER2 amplification compared with HER2 nonamplified patients (2.8 v 8.1 months, respectively; hazard ratio [HR], 7.05; 95% CI, 3.4 to 14.9; P < .001). These findings were validated in cohort 2 (median PFS for HER2 amplified v nonamplified: 2.8 v 9.3 months, respectively; HR, 10.66; 95% CI, 4.5 to 25.1; P < .001). The median PFS on therapy without anti-EGFRabs was similar among HER2-amplified and nonamplified patients in both cohort 1 (9.7 v 11.1 months, respectively; HR, 1.01; 95% CI, 0.4 to 2.4; P = .97) and cohort 2 (9.6 v 11.3 months, respectively; HR, 1.21; 95% CI, 0.5 to 3.1; P = .66). In multivariable analyses, HER2 amplification emerged as a single independent predictor of poor PFS on anti-EGFRab therapy in both cohort 1 (HR, 6.48; 95% CI, 3.1 to 13.6; P < .001) and cohort 2 (HR, 10.1; 95% CI, 4.3 to 23.9; P < .001). Conclusion: HER2 amplification in RAS/RAF wild-type mCRC seems to be a predictive biomarker for lack of efficacy of anti-EGFRab therapy. Screening patients with RAS/BRAF wild-type mCRC for HER2 amplification should be considered before anti-EGFRab treatment to guide therapy and to identify patients for early referral to clinical trials.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the prognostic relevance of ERBB2 amplification itself in mCRC remains controversial.42 43 45”
From Current and emerging concepts for systemic treatment of metastatic colorectal cancer (2025) · cites this paper as [43]
Citations
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302
Wolff, A. C., Hammond, M. E. H., Hicks, D. G., Dowsett, M., McShane, L. M., Allison, K. H., Allred, D. C., Bartlett, J. M. S., Bilous, M., Fitzgibbons, P. L., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.9984 · Cited by 4,080
Trastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Geyer, C. E., Forster, J. K., Lindquist, D. L., Chan, S. Y. T., Romieu, C. G., Pieńkowski, T., Jagiełło-Gruszfeld, A., Crown, J. P., Chan, A., Kaufman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa064320 · Cited by 3,458
Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305275 · Cited by 2,263
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Swain, S. M., Baselga, J., Kim, S.-B., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Heeson, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1413513 · Cited by 2,164
Frampton, G. M., Fichtenholtz, A., Otto, G. A., Wang, K., Downing, S. R., He, J., Schnall-Levin, M., White, J., Sanford, E. M., An, P., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2696 · Cited by 2,157
Research works printed but not linked: 2
- Gabriel S, 2009, ., 2, Unit 2.12
- Wulfkuhle JD, 2018, Precis Oncol, 1
Cited by
Sorted by citations
Meric-Bernstam, F., Hurwitz, H., Raghav, K. P. S., McWilliams, R. R., Fakih, M., VanderWalde, A., Swanton, C., Kurzrock, R., Burris, H., Sweeney, C., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30904-5 · Cited by 573
Self-citationClinical management of metastatic colorectal cancer in the era of precision medicine
Ciardiello, F., Ciardiello, D., Martini, G., Napolitano, S., Tabernero, J. M., & Cervantes, A. M. R. (2022) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21728 · Cited by 556
Siena, S., Bartolomeo, M. D., Raghav, K. P. S., Masuishi, T., Loupakis, F., Kawakami, H., Yamaguchi, K., Nishina, T., Fakih, M., Élez, E., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00086-3 · Cited by 436
Self-citationBiomarker-guided therapy for colorectal cancer: strength in complexity
Sveen, A., Kopetz, S., & Lothe, R. A. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0241-1 · Cited by 320
Self-citationGenomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer
Strickler, J. H., Loree, J. M., Ahronian, L. G., Parikh, A. R., Niedzwiecki, D., Pereira, A. A. L., McKinney, M. S., Korn, W. M., Atreya, C. E., Banks, K. C., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1009 · Cited by 300
Self-citationUnderstanding the role of primary tumour localisation in colorectal cancer treatment and outcomes
Stintzing, S., Tejpar, S., Gibbs, P., Thiebach, L., & Lenz, H. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.07.016 · Cited by 278
Modern therapeutic approaches for the treatment of malignant liver tumours
Petrowsky, H., Fritsch, R., Gückenberger, M., Oliveira, M. L. D., Dutkowski, P., & Clavien, P. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0314-8 · Cited by 252
Ross, J. S., Fakih, M., Ali, S. M., Elvin, J. A., Schrock, A. B., Suh, J. H., Vergilio, J., Ramkissoon, S. H., Severson, E. A., Daniel, S., et al. (2018) · Cancer · doi:10.1002/cncr.31125 · Cited by 218
Self-citationYoshino, T., Di Bartolomeo, M., Raghav, K., Masuishi, T., Loupakis, F., Kawakami, H., Yamaguchi, K., Nishina, T., Wainberg, Z., Elez, E., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38032-4 · Cited by 178
Self-citationHER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer
Bianchi, A. S., Amatu, A., Porcu, L., Ghezzi, S., Lonardi, S., Leone, F., Bergamo, F., Fenocchio, E., Martinelli, E., Borelli, B., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0785 · Cited by 174
Raghav, K. P. S., Siena, S., Takashima, A., Kato, T., den Eynde, M. V., Pietrantonio, F., Komatsu, Y., Kawakami, H., Peeters, M., André, T., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00380-2 · Cited by 169
Self-citationTherapeutic landscape and future direction of metastatic colorectal cancer
Bando, H., Ohtsu, A., & Yoshino, T. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00736-1 · Cited by 151
HER2-targeted therapies in cancer: a systematic review
Zhu, K., Yang, X., Tai, H., Zhong, X., Luo, T., & Zheng, H. Y. (2024) · Biomarker Research · doi:10.1186/s40364-024-00565-1 · Cited by 170
Parseghian, C. M., Napolitano, S., Loree, J. M., & Kopetz, S. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0823 · Cited by 124
Self-citationDiagnosis and Treatment of ERBB2-Positive Metastatic Colorectal Cancer
Strickler, J. H., Yoshino, T., Graham, R. P., Siena, S., & Bekaii‐Saab, T. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2021.8196 · Cited by 106
Ahcene Djaballah, S., Daniel, F., Milani, A., Ricagno, G., & Lonardi, S. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_351354 · Cited by 95
Filip, S., Vymetalkova, V. P., Petera, J., Vodičková, Ľ., Kubeček, O., John, S., Čečka, F., Krupova, M., Manethová, M., Červená, K., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155255 · Cited by 86
The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer
Taïeb, J., Jung, A., Bianchi, A. S., Peeters, M., Seligmann, J. F., Zaanan, A., Burdon, P., Montagut, C. O., & Laurent‐Puig, P. (2019) · Drugs · doi:10.1007/s40265-019-01165-2 · Cited by 78
Molecular Pathways and Mechanisms of HER2 in Cancer Therapy
Raghav, K. P. S., & Moasser, M. M. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0283 · Cited by 65
Self-citationMartini, G., Ciardiello, D., Vitiello, P. P., Napolitano, S., Cardone, C., Cuomo, A., Troiani, T., Ciardiello, F., & Martinelli, E. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102023 · Cited by 59
Immune Resistance and EGFR Antagonists in Colorectal Cancer
Giordano, G., Remo, A., Porrás, A., & Pancione, M. (2019) · Cancers · doi:10.3390/cancers11081089 · Cited by 54
Dumbrava, E. E. I., Balaji, K., Raghav, K. P. S., Hess, K. R., Javle, M. M., Blum-Murphy, M. A., Ajani, J. A., Kopetz, S., Broaddus, R. R., Routbort, M. J., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00345 · Cited by 56
Self-citationRusso, V., Lallo, E., Munnia, A., Spedicato, M., Messerini, L., D’Aurizio, R., Ceroni, E. G., Brunelli, G., Galvano, A., Russo, A., et al. (2022) · Cancers · doi:10.3390/cancers14164012 · Cited by 52
Molecular subtypes and the evolution of treatment management in metastatic colorectal cancer
Martini, G., Dienstmann, R., Ros, J., Baraibar, I., Cuadra‐Urteaga, J. L., Salvà, F., Ciardiello, D., Mulet-Margalef, N., Argilés, G., Tabernero, J. M., et al. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920936089 · Cited by 57
HER2 as a Predictive Biomarker and Treatment Target in Colorectal Cancer
Cuyper, A. D., den Eynde, M. V., & Machiels, J. (2020) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2020.02.007 · Cited by 51
Current and Emerging Biomarkers in Metastatic Colorectal Cancer
Lee, M. K. C., & Loree, J. M. (2019) · Current Oncology · doi:10.3747/co.26.5719 · Cited by 50
Self-citationCetuximab as a Key Partner in Personalized Targeted Therapy for Metastatic Colorectal Cancer
Gonzalez, N. S., Ros, J., Baraibar, I., Salvà, F., Rodríguez-Castells, M., Alcaráz, A., García, A., Tabernero, J. M., & Élez, E. (2024) · Cancers · doi:10.3390/cancers16020412 · Cited by 50
Rachiglio, A. M., Lambiase, M., Fenizia, F., Roma, C., Cardone, C., Iannaccone, A., Luca, A. D., Carotenuto, M., Frezzetti, D., Martinelli, E., et al. (2019) · Cancers · doi:10.3390/cancers11060859 · Cited by 43
HER2 targeted therapy in colorectal cancer: New horizons
Suwaidan, A. A., Lau, D. K., & Chau, I. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102363 · Cited by 45
Circulating Tumor DNA to Drive Treatment in Metastatic Colorectal Cancer
Patelli, G., Mauri, G., Tosi, F., Amatu, A., Bencardino, K. B., Bonazzina, E. F., Pizzutilo, E. G., Villa, F., Calvanese, G., Agostara, A. G., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0079 · Cited by 44
Current and emerging concepts for systemic treatment of metastatic colorectal cancer
Steup, C., Kennel, K. B., Neurath, M. F., Fichtner-Feigl, S., & Greten, F. R. (2025) · Gut · doi:10.1136/gutjnl-2025-335412 · Cited by 39
Gutierrez, M. E., Price, K. S., Lanman, R. B., Nagy, R. J., Shah, I., Mathura, S., Mulcahy, M., Norden, A. D., & Goldberg, S. L. (2019) · JCO Precision Oncology · doi:10.1200/po.19.00274 · Cited by 39
Beyond RAS and BRAF: HER2, a New Actionable Oncotarget in Advanced Colorectal Cancer
Guarini, C., Grassi, T., Pezzicoli, G., & Porta, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136813 · Cited by 41
Bekaii-Saab, T. S., Lach, K., Hsu, L.-I., Siadak, M., Stecher, M., Ward, J., Beckerman, R., & Strickler, J. H. (2023) · The Oncologist · doi:10.1093/oncolo/oyad200 · Cited by 36
Loree, J. M., Kopetz, S., & Raghav, K. P. S. (2017) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2017.01.01 · Cited by 36
Self-citationRecent Advances in Monoclonal Antibody Therapy for Colorectal Cancers
Hwang, K., Yoon, J. H., Lee, J., & Lee, S. (2021) · Biomedicines · doi:10.3390/biomedicines9010039 · Cited by 37
Targeted Therapy in Metastatic Colorectal Cancer: Current Standards and Novel Agents in Review
DeStefanis, R. A., Kratz, J. D., Emmerich, P. B., & Deming, D. A. (2019) · Current Colorectal Cancer Reports · doi:10.1007/s11888-019-00430-6 · Cited by 34
Current concepts of anti-EGFR targeting in metastatic colorectal cancer
Doleschal, B., Petzer, A., & Rumpold, H. F. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1048166 · Cited by 36
Anti-EGFR Therapy in Metastatic Colorectal Cancer: Identifying, Tracking, and Overcoming Resistance
Leite, L. F., Noronha, M. M., de Menezes, J. S. A., da Conceição, L. D., Almeida, L. F. C., Cappellaro, A. P., Belotto, M., Biachi de Castria, T., Peixoto, R. D., & Megid, T. B. C. (2025) · Cancers · doi:10.3390/cancers17172804 · Cited by 32
Siena, S., Raghav, K., Masuishi, T., Yamaguchi, K., Nishina, T., Elez, E., Rodriguez, J., Chau, I., Di Bartolomeo, M., Kawakami, H., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53223-3 · Cited by 30
Self-citationFu, X., Ying, J., Liu, Y., Fang, W. J., Han, W., Hu, H., Zhang, S., & Yuan, Y. (2022) · Cancer Science · doi:10.1111/cas.15660 · Cited by 30
Wang, N., Cao, Y., Si, C., Shao, P., Su, G., Wang, X., Bao, J., & Liu, Y. (2022) · Cancers · doi:10.3390/cancers14205160 · Cited by 29
Voutsadakis, I. A. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.103987 · Cited by 31
Singh, H., Kang, A., Bloudek, L. M., Hsu, L., Palanca-Wessels, M. C., Stecher, M., Siadak, M. F., & Ng, K. (2023) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkad082 · Cited by 27
Prognostic and Predictive Determinants of Colorectal Cancer: A Comprehensive Review
Cotan, H. T., Emilescu, R. A., Iaciu, C. I., Orlov-Slavu, C. M., Olaru, M., Popa, A. M., Jinga, M., Niţipir, C., Schreiner, O. D., & Ciobanu, R. C. (2024) · Cancers · doi:10.3390/cancers16233928 · Cited by 27
Tomasini, P. P., Guecheva, T. N., Leguisamo, N. M., Péricart, S., Brunac, A., Hoffmann, J., & Saffi, J. (2021) · Cancers · doi:10.3390/cancers13133130 · Cited by 25
Prognostic and predictive molecular biomarkers in colorectal cancer
Zhang, J., Zhu, H., Liu, W., Miao, J., Mao, Y., & Li, Q. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1532924 · Cited by 24
Biomarkers for predicting the outcome of various cancer immunotherapies
Jafarzadeh, L., Khakpoor-Koosheh, M., Mirzaei, H., & Mirzaei, H. R. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103161 · Cited by 21
New developments in targeted therapy for metastatic colorectal cancer
Wong, A. H. N., Ma, B. B. Y., & Lui, R. N.-S. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221148540 · Cited by 23
Colorectal Cancer Liver Metastases: Genomics and Biomarkers with Focus on Local Therapies
Kitsel, Y., Cooke, T., Sotirchos, V. S., & Sofocleous, C. T. (2023) · Cancers · doi:10.3390/cancers15061679 · Cited by 24
Conticchio, M., Uldry, É., Hübner, M., Digklia, A., Fraga, M., Sempoux, C. L., Raisaro, J. L., & Fuks, D. (2025) · Cancers · doi:10.3390/cancers17152539 · Cited by 23
Biomarker-driven and molecular targeted therapies for colorectal cancers
Schirripa, M., Cohen, S. A., Battaglin, F., & Lenz, H. (2017) · Seminars in Oncology · doi:10.1053/j.seminoncol.2017.06.003 · Cited by 25
HER2 targeted therapy in colorectal Cancer: Current landscape and future directions
Chen, N., He, L. T., Zou, Q., & Deng, H. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116101 · Cited by 22
Battaglin, F., Ou, F., Qu, X., Höchster, H. S., Niedzwiecki, D., Goldberg, R. M., Mayer, R. J., Ashouri, K., Zemla, T., Blanke, C. D., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.01507 · Cited by 21
Molecular Basis of HER2-Targeted Therapy for HER2-Positive Colorectal Cancer
Yoshikawa, A., & Nakamura, Y. (2022) · Cancers · doi:10.3390/cancers15010183 · Cited by 21
Treatment options for HER2-expressing colorectal cancer: updates and recent approvals
Zheng-Lin, B., & Bekaii‐Saab, T. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231225037 · Cited by 24
Exploring Predictive and Prognostic Biomarkers in Colorectal Cancer: A Comprehensive Review
Ashouri, K., Wong, A., Mittal, P., Torres‐Gonzalez, L., Lo, J. H., Soni, S., Algaze, S. D., Khoukaz, T., Zhang, W., Yang, Y., et al. (2024) · Cancers · doi:10.3390/cancers16162796 · Cited by 20
The Position of Circulating Tumor DNA in the Clinical Management of Colorectal Cancer
de Abreu, A. R., de Beeck, K. O., Laurent‐Puig, P., Taly, V., & Benhaïm, L. (2023) · Cancers · doi:10.3390/cancers15041284 · Cited by 17
The emerging HER2 landscape in colorectal cancer: the key to unveil the future treatment algorithm?
Venturini, J., Massaro, G., Lavacchi, D., Rossini, D., Pillozzi, S., Caliman, E., Pellegrini, E., & Antonuzzo, L. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104515 · Cited by 18
Wang, C., Sandhu, J. S., & Fakih, M. (2022) · The Oncologist · doi:10.1093/oncolo/oyab028 · Cited by 16
Self-citationCann, C., LaPelusa, M. B., Cimino, S. K., & Eng, C. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1176950 · Cited by 16
Spiekman, I. A. C., Zeverijn, L. J., Geurts, B. S., Verkerk, K., Mohammad, S. F. H., van der Noort, V., Roepman, P., de Leng, W. W. J., Jansen, A. M. L., Gootjes, E. C., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.113988 · Cited by 16
Torres-Jiménez, J., Esteban-Villarrubia, J., Ferreiro, R., & Carrato, A. (2021) · Cancers · doi:10.3390/cancers13235938 · Cited by 15
Babkoff, A., Zick, A., Hubert, A., Tarantino, P., & Grinshpun, A. (2024) · ESMO Gastrointestinal Oncology · doi:10.1016/j.esmogo.2023.100032 · Cited by 14
Primary and acquired resistance to biologic therapies in gastrointestinal cancers
Lubner, S. J., Uboha, N. V., & Deming, D. A. (2017) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2017.01.16 · Cited by 14
Tumor Biomarker Testing for Metastatic Colorectal Cancer: a Canadian Consensus Practice Guideline
Yu, I. S., Aubin, F., Goodwin, R. A., Loree, J. M., Mather, C. A., Sheffield, B. S., Snow, S. L., & Gill, S. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221111705 · Cited by 17
Self-citationHER2-Positive Metastatic Colorectal Cancer
Robinson, H. R., Messersmith, W. A., & Lentz, R. W. (2024) · Current Treatment Options in Oncology · doi:10.1007/s11864-024-01183-7 · Cited by 15
Lee, S. M., & Oh, H. (2024) · Scientific Reports · doi:10.1038/s41598-024-62096-x · Cited by 14
Advances and challenges in targeted therapies for HER2-amplified colorectal cancer
Pizzamiglio, M., Soulabaille, A., Lahlou, W., Pilla, L., Zaanan, A., & Taı̈eb, J. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115471 · Cited by 16
Foroughi, S., Tie, J., Gibbs, P., & Burgess, A. W. (2019) · Growth Factors · doi:10.1080/08977194.2019.1703702 · Cited by 12
Advances in Targeting HER2 across Cancer Subtypes: A Pan-Tumor Approach
Adesoye, T., Dumbrava, E. E. I., Raghav, K. P. S., Şahin, A. A., Chen, H., Lee, S. S., Javle, M. M., Pant, S., Alhalabi, O., Le, X., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-1982 · Cited by 17
Self-citationZhang, R., Su, C., Jia, Y.-L., Xing, M., Jin, S., & Zong, H. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117363 · Cited by 16
Narita, Y., Yoshimoto, T., Namai, T., Asakawa, T., Kawakami, S., Gower‐Page, C., Reyes‐Rivera, I., Patel, A., & Nakamura, Y. (2022) · JCO Clinical Cancer Informatics · doi:10.1200/cci.22.00022 · Cited by 12
Vaghi, C., Tosi, F., Mauri, G., Bonazzina, E., Amatu, A., Bencardino, K., Piscazzi, D., Roazzi, L., Villa, F., Maggi, M., et al. (2026) · Drugs · doi:10.1007/s40265-025-02253-2 · Cited by 11
Colorectal Cancer Liver Metastasis—State-of-the-Art and Future Perspectives
Ruivo, A. D. S., Oliveira, R. C., Silva-Vaz, P., & Tralhão, J. G. (2023) · Gastrointestinal Disorders · doi:10.3390/gidisord5040046 · Cited by 13
Heilmann, A. M., Riess, J. W., McLaughlin-Drubin, M. E., Huang, R. S. P., Hjulstrom, M., Creeden, J., Alexander, B. M., & Erlich, R. (2023) · The Oncologist · doi:10.1093/oncolo/oyad251 · Cited by 9
Beyond EGFR inhibitors in advanced colorectal cancer: Targeting BRAF and HER2
Dao, V. A., & Heestand, G. M. (2023) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2023.100960 · Cited by 9
Resistance to Anti-HER2 Therapies in Gastrointestinal Malignancies
Mo, C., Sterpi, M., Jeon, H., & Bteich, F. (2024) · Cancers · doi:10.3390/cancers16162854 · Cited by 8
Optimizing Biologic Sequencing in Metastatic Colorectal Cancer: First Line and Beyond
Jin, Z., & Hubbard, J. M. (2019) · Current Oncology · doi:10.3747/co.26.5589 · Cited by 8
Pharmacogenomics in colorectal cancer: current role in clinical practice and future perspectives
Battaglin, F., Puccini, A., Naseem, M., Schirripa, M., Berger, M. D., Tokunaga, R., McSkane, M., Khoukaz, T., Soni, S., Zhang, W., et al. (2018) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2018.04 · Cited by 8
Rachiglio, A. M., Sacco, A., Forgione, L., Esposito, C., Chicchinelli, N., & Normanno, N. (2020) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2020.00004 · Cited by 9
Thavaneswaran, S., Lin, F. P. Y., Grady, J. P., Espinoza, D., Huang, M., Chinchen, S., Sebastian, L. T., Kansara, M., Mersiades, T., Lee, C. K., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00698-4 · Cited by 7
Gonzalez, N. S., Marchese, P. V., Baraibar, I., Ros, J., Salvà, F., Rodrı́guez, M., Salvà, C., Vaghi, C., Alcaráz, A., García, A., et al. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2349287 · Cited by 6
Cibler HER2 dans le cancer colorectal
Spitzer, E., Cervera, P., André, T., & Cohen, R. (2023) · Bulletin du Cancer · doi:10.1016/j.bulcan.2023.01.013 · Cited by 7
Wang, C., & Fakih, M. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.7023 · Cited by 7
Self-citationHoyek, C., Zheng-Lin, B., Jones, J. C., & Bekaii‐Saab, T. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2472411 · Cited by 5
Alfonso, P. G., Valladares‐Ayerbes, M., Martín, A. J. M., Herrero, R. M., Muñoz, E. G., & Prat-Llorens, G. (2025) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2025.2477192 · Cited by 5
Frequency of Her2-low in colorectal cancer and its relations with the tumor microenvironment
Lang‐Schwarz, C., Vieth, M. W., Dregelies, T., & Sterlacci, W. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154417 · Cited by 5
Damato, A., Rotolo, M., Caputo, F., Borghi, E., Iachetta, F., & Pinto, C. (2022) · Life · doi:10.3390/life12081137 · Cited by 5
Precision oncology giveth and precision oncology taketh away
Saltz, L. B. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30095-6 · Cited by 5
Emiloju, O. E., Zhu, M., Xie, H., Jin, Z., Sinicrope, F. A., & Hubbard, J. M. (2023) · Current Treatment Options in Oncology · doi:10.1007/s11864-023-01142-8 · Cited by 4
Radić, J., Nikolić, I., Kolarov-Bjelobrk, I., Vasiljević, T., Djurić, A., Vidović, V., & Kožik, B. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14080879 · Cited by 4
Antoniotti, C., Ongaro, E., Falcone, A., & Cremolini, C. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082298 · Cited by 4
Siena, S., Chalabi, M., Goodwin, R. A., Osterlund, P. J., Penault-Llorca, F. M., Sartore-Bianchi, A., Starling, N., Stintzing, S., & Tabernero, J. M. (2026) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2026.103097 · Cited by 3
Jang, J. Y., Jeon, Y., Jeong, S. Y., Lim, S. H., Park, Y. S., Lim, H. Y., Lee, J. Y., & Kim, S. T. (2023) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-23-375 · Cited by 3
Current Status of Precision Medicine in Colorectal Cancer in Japan
Kojitani, Y., & Takeda, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115029 · Cited by 3
Jacome, A. A. D. A., & Johnson, B. (2021) · EMJ Oncology · doi:10.33590/emjoncol/21-00122 · Cited by 3
Kaur, S., Gill, K. S., Manjari, M., Kumar, S., Nauhria, S., Nath, R., Patel, C., Hamdan, K., Jeong, Y., Nayak, N. P., et al. (2022) · Cureus · doi:10.7759/cureus.22811 · Cited by 3
Meng, G., Yang, S., & Chen, F. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.983092 · Cited by 3
Barzi, A., Weipert, C. M., Espenschied, C. R., & Lenz, H. (2020) · Journal of Adolescent and Young Adult Oncology · doi:10.1089/jayao.2020.0080 · Cited by 3
Metadata
- Authors
- Raghav, K., Loree, J. M., Morris, J. S., Overman, M. J., Yu, R., Meric-Bernstam, F., Menter, D., Korphaisarn, K., Kee, B., Muranyi, A., Singh, S., Routbort, M., Chen, K., Shaw, K. R. M., Katkhuda, R., Shanmugam, K., Maru, D., Fakih, M., & Kopetz, S.
- Affiliations
- City Of Hope National Medical Center (US)
- Kanwal Raghav, Jonathan M. Loree, Jeffrey S. Morris, Michael J. Overman, Ruoxi Yu, Funda Meric-Bernstam, David Menter, Krittiya Korphaisarn, Brian Kee, Mark Routbort, Ken Chen, Kenna R.M. Shaw, Riham Katkhuda, Dipen Maru, and Scott Kopetz, The University of Texas MD Anderson Cancer Center, Houston, TX; Andrea Muranyi, Shalini Singh, and Kandavel Shanmugam, Ventana Medical Systems, Tucson, AZ; and Marwan Fakih, City of Hope Comprehensive Cancer Center, Duarte, CA.
- ORCID
- Venue
- JCO Precision Oncology
- Published
- 2019-12
- Volume
- 3
- Issue
- 3
- Pages
- 1-13
- ISSN
- 2473-4284 (ISSN-L)
- OpenAlex
- W2912216712
- Cited by
- 132
- References
- 31
- Citations by year
- 2026: 10 · 2025: 17 · 2024: 24 · 2023: 20 · 2022: 20 · 2021: 9 · 2020: 8 · 2019: 15
- FWCI
- 5.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- JCO Precision Oncology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- HER2 amplification, metastatic colorectal cancer, anti-EGFR antibody therapy, predictive biomarkers, progression-free survival, RAS/BRAF wild-type, treatment resistance, HER2/CEP17 ratio, next-generation sequencing, anti-EGFR therapy, biomarker validation, prognostic factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
